Аннотация

Ниқрис – бемории метаболикӣ буда, паҳншавии он 1–4% ро ташкил медиҳад ва бо артрити шадид зоҳир мегардад. Дар занон ин беморӣ асосан пас аз менопауза зоҳир мешавад, дар заминаи полиморбидӣ (фишорбаландии шараёнӣ, диабети қанд, бемории музмини гурда, патологияи дилу рагҳо) ҷараён мегирад ва бо вайроншавии бештарини фаъолияти функсионалӣ алоқаманд аст. Дар ин баррасии илмӣ хусусиятҳои гендерии патогенез, клиника ва фармакотерапияи ниқрис таҳлил шудаанд. Таъкид мегардад, ки имтидоди маълумоти тадқиқотҳое, ки асосан мардонро дар бар мегиранд, метавонад нодуруст бошад. Самаранокӣ ва бехатарии ингибиторҳои ксантиноксидаза (аллопуринол, фебуксостат), маводҳои урикозурикӣ ва доруҳои барои рафъи ҳуҷумҳои шадид дар занон баррасӣ шудааст. Ба мушкилоти табобат, ки бо патологияи ҳамроҳ вобастаанд, таваҷҷуҳи махсус дода шудааст. Ҷустуҷӯи манбаъҳои адабӣ дар пойгоҳҳои маълумотии PubMed, MEDLINE, Scopus, Web of Science, КиберЛенинка ва ELIBRARY барои солҳои 2018–2024 бо истифодаи калимаҳои калидии «ниқрис», «гиперурикемия», «занон», «фарқиятҳои гендерӣ», «фармакотерапия» анҷом дода шуд.

Калимаҳои калидӣ

ниқрис занон гиперурикемия фармакотерапия коморбидият.

Матни пурра

Боргирӣ кардани мақола дар PDF

Версияи пурраи мақола дар формати PDF

Феҳристи манбаъ

  1. Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50(3S):11–16. DOI: 10.1016/j.semarthrit.2020.04.008
  2. Dalbeth N, Bardin T, Doherty M, Pascual E, Barskova V, Conaghan P, et al. Discordant American College of Physicians and international Rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol. 2017;13(9):561–568. DOI: 10.1038/nrrheum.2017.126
  3. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879–895. DOI: 10.1002/art.41247
  4. Tsurko VV, Gromova MA. Gender differences in gout course and response to xanthine oxidase inhibitors. Meditsinskiy sovet. 2021;(19):164–169. DOI: 10.21518/2079-701X-2021-19-164-169 (In Russ.)
  5. Te Kampe R, Janssen M, van Durme C, van Onna M, Arts ICW, Boonen A, et al. Sex differences in the clinical profile among patients with gout: cross-sectional analyses of an observational study. J Rheumatol. 2021;48(2):286–292. DOI: 10.3899/jrheum.200113
  6. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: NHANES 2007–2016. Arthritis Rheumatol. 2019;71(6):991–999. DOI: 10.1002/art.40807
  7. Major TJ, Topless RK, Dalbeth N, Merriman TR. Evaluation of diet-wide contribution to serum urate levels: meta-analysis of population-based cohorts. BMJ. 2018;363:k3951. DOI: 10.1136/bmj.k3951
  8. Ignatenko GA, Mukhin IV, Prisyazhnyuk MV, Palamarchuk YuS, Panieva NYu. Gender differences in purine and thyroid metabolism relationships in gout. Universitetskaya klinika. 2022;1(42):5–12. (In Russ.)
  9. Narang RK, Topless R, Cadzow M, Stamp LK, Dalbeth N, Merriman TR, et al. Interactions between serum urate-associated genetic variants and sex on gout risk: UK Biobank analysis. Arthritis Res Ther. 2019;21(1):13. DOI: 10.1186/s13075-018-1787-5
  10. Shostak NA, Pravdyuk NG, Loginova TK, Lazarenko GN. Hyperuricemia, gout and comorbidity. Klinitsist. 2022;16(3):58–64. DOI: 10.17650/1818-8338.2022.16.3.K648 (In Russ.)
  11. Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, et al. Sex differences in gout characteristics: tailoring care. BMC Musculoskelet Disord. 2017;18(1):108. DOI: 10.1186/s12891-017-1465-9
  12. Sumpter NA, Takei R, Cadzow M, Topless RKG, Phipps-Green AJ, Murphy R, et al. Association of gout polygenic risk score with age at onset and tophaceous disease. Arthritis Rheumatol. 2023;75(5):816–825. DOI: 10.1002/art.42393
  13. Lebedev PA, Garanin AA, Novichkova NL. Pharmacotherapy of gout: modern approaches and перспективы. Sovremennaya revmatologiya. 2021;15(4):107–112. DOI: 10.14412/1996-7012-2021-4-107-112 (In Russ.)
  14. Belyaeva IB, Mazurov VI, Petrova MS, Bashkinov RA. Modern strategy for gout treatment: focus on symptom-modifying and urate-lowering drugs. Effektivnaya farmakoterapiya. 2024;20(25):44–49. DOI: 10.33978/2307-3586-2024-20-25-44-49 (In Russ.)
  15. Pillinger MH, Mandell BF. Therapeutic approaches in gout treatment. Semin Arthritis Rheum. 2020;50(3S):24–30. DOI: 10.1016/j.semarthrit.2020.04.010
  16. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR recommendations for gout management. Ann Rheum Dis. 2017;76(1):29–42. DOI: 10.1136/annrheumdis-2016-209707
  17. Panevin TS, Eliseev MS, Nasonov EL. Urate-lowering drugs in gout treatment: unknown about known. Nauchno-prakticheskaya revmatologiya. 2021;59(6):727–737. (In Russ.)
  18. Perez-Ruiz F, Dalbeth N. Combination urate-lowering therapy in gout: evidence review. Semin Arthritis Rheum. 2019;48(4):658–668. DOI: 10.1016/j.semarthrit.2018.06.004
  19. Mizuno T, Hayashi T, Hikosaka S, Shimabukuro Y, Murase M, Takahashi K, Hayashi H. Efficacy and safety of febuxostat in elderly female patients. Clin Interv Aging. 2014;9:1489–1493. DOI: 10.2147/CIA.S70855
  20. Bashkova IB, Madyanov IV. Febuxostat as an effective urate-lowering therapy in gout (clinical case). Meditsinskiy sovet. 2022;16(14):137–144. DOI: 10.21518/2079-701X-2022-16-14-137-144 (In Russ.)
  21. Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, et al. Cardiovascular risk in gout patients initiating febuxostat vs allopurinol. Circulation. 2018;138(11):1116–1126. DOI: 10.1161/CIRCULATIONAHA.118.033992
  22. Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, et al. Long-term cardiovascular safety of febuxostat vs allopurinol (FAST trial). Lancet. 2020;396(10264):1745–1757. DOI: 10.1016/S0140-6736(20)32234-0
  23. Garanin AA, Novichkova NL, Lebedev PA. Prospects of anti-inflammatory and urate-lowering therapy in gout. Nauchno-prakticheskaya revmatologiya. 2022;60(2):205–213. (In Russ.)
  24. Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid in gout. J Rheumatol. 2013;40(6):872–876. DOI: 10.3899/jrheum.121301
  25. Karageorgiou I, Javed Z, Grooms A, Patel R, Singh J, Ahmed A, et al. Monitoring uric acid therapy in gout and CKD. Cureus. 2025;17(1):e77813. DOI: 10.7759/cureus.77813
  26. Kunitskaya NA. Gout: new therapeutic strategies. Vrach. 2021;32(6):16–21. DOI: 10.29296/25877305-2021-06-04 (In Russ.)
  27. Chikina MN, Eliseev MS, Zhelyabina OV. Comparison of anti-inflammatory drugs during urate-lowering therapy initiation. Sovremennaya revmatologiya. 2021;15(2):50–56. DOI: 10.14412/1996-7012-2021-2-50-56 (In Russ.)
  28. Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi HK. Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis. 2014;73(2):385–390. DOI: 10.1136/annrheumdis-2012-202589
  29. Navarra S, Rubin BR, Yu Q, Smugar SS, Tershakovec AM. Response to etoricoxib vs indomethacin in acute gout. Curr Med Res Opin. 2007;23(7):1685–1691. DOI: 10.1185/030079907x210750
  30. Eliseev MS, Chikina MN, Zhelyabina OV. Colchicine for prevention of acute gout flares. Sovremennaya revmatologiya. 2021;15(4):50–55. DOI: 10.14412/1996-7012-2021-4-50-55 (In Russ.)
  31. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High vs low dosing of colchicine in acute gout flare. Arthritis Rheum. 2010;62(4):1060–1068. DOI: 10.1002/art.27327
  32. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Prednisolone vs naproxen in gout arthritis. Lancet. 2008;371(9627):1854–1860. DOI: 10.1016/S0140-6736(08)60799-0
  33. Patel AV, Gaffo AL. Managing gout in women. J Inflamm Res. 2022;15:1591–1598. DOI: 10.2147/JIR.S2847
  34. Prozherina Yu, Shirokova I. Gout: updates in clinical guidelines. Remedium. 2021;(2):58–61. (In Russ.)
  35. Sinenko AA, Mikheeva AA, Lindeman IK, Lupach NM. Anakinra in severe refractory gout. Universum: medicina i farmakologiya. 2025;1(6):27–32. (In Russ.)
  36. Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra efficacy in refractory gout: case series. Semin Arthritis Rheum. 2010;40(3):210–214. DOI: 10.1016/j.semarthrit.2010.03.001
  37. Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen TLTA, Janssen M, Kok MR, et al. Anakinra for acute gout flares: randomized trial. Rheumatology (Oxford). 2019;58(8):1344–1352. DOI: 10.1093/rheumatology/key402
  38. Thueringer JT, Doll NK, Gertner E. Anakinra in severe gout in ICU patients. Semin Arthritis Rheum. 2015;45(1):81–85. DOI: 10.1016/j.semarthrit.2015.02.006
  39. Liew JW, Gardner GC. Use of anakinra in hospitalized patients with crystal arthritis. J Rheumatol. 2019;46(10):1345–1349. DOI: 10.3899/jrheum.181018